Literature DB >> 3946108

Biotin-responsive encephalopathy with myoclonus, ataxia, and seizures.

S Bressman, S Fahn, M Eisenberg, M Brin, W Maltese.   

Abstract

Prominent neurological abnormalities, including myoclonus, seizures, ataxia, and hearing loss, have been noted in juvenile-onset biotin-responsive MCD. The underlying defect in many of these patients, who generally present in the first year of life, appears to be a deficiency of biotinidase. We have presented a young woman with adult-onset myoclonus, ataxia, hearing loss, seizures, hemianopia, and hemiparesis who responded to pharmacologic dosages of biotin. Although she displayed many of the clinical and biochemical features of juvenile-onset MCD, she did not have a biotinidase deficiency, and the underlying defect remains to be determined. Because of her response to biotin, we have advocated that other patients with unexplained myoclonus syndromes be evaluated for biotin-dependent carboxylase deficiencies and undergo a therapeutic trial with biotin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946108

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  4 in total

1.  Progressive Myoclonic Epilepsies.

Authors:  Basim M. Uthman; Andreas Reichl
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

2.  Brainstem-mediated locomotion and myoclonic jerks. I. Neural substrates.

Authors:  Y Y Lai; J M Siegel
Journal:  Brain Res       Date:  1997-01-16       Impact factor: 3.610

Review 3.  Movement disorders and inborn errors of metabolism in adults: a diagnostic approach.

Authors:  F Sedel; J-M Saudubray; E Roze; Y Agid; M Vidailhet
Journal:  J Inherit Metab Dis       Date:  2008-05-30       Impact factor: 4.750

4.  Effect of biotin supplementation on neuropathic pain induced by chronic constriction of the sciatic nerve in the rat.

Authors:  Ali-Reza Abed; Alireza Abed; Hamid Reza Banafshe; Ebadallah Shiri Malekabad; Sattar Gorgani-Firuzjaee; Ali-Reza Dadashi
Journal:  Res Pharm Sci       Date:  2021-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.